Literature DB >> 9028947

Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules.

C P Hayward1, E M Cramer, W H Kane, S Zheng, M Bouchard, J M Massé, G E Rivard.   

Abstract

We recently described a Quebec family with an autosomal dominant bleeding disorder characterized by mildly reduced-low normal platelet counts, an epinephrine aggregation defect, multimerin deficiency, and proteolytic degradation of several, soluble alpha-granular proteins. Similar clinical features led us to investigate a second family with an unexplained, autosomal dominant bleeding disorder. The affected individuals had reduced to normal platelet counts, absent platelet aggregation with epinephrine, and multimerin deficiency. Their platelet alpha-granular proteins factor V, thrombospondin, von Willebrand factor, fibrinogen, fibronectin, osteonectin, and P-selectin were proteolyzed and comigrated with the degradation products found in patients from the other family. However, their platelet albumin, IgG, external membrane glycoproteins, CD63 (a lysosomal and dense granular protein), calpain, and plasma von Willebrand factor were normal, indicating restriction in the proteins proteolyzed. Electron microscopy studies indicated preserved alpha-granular ultrastructure, despite degradation of soluble and membrane alpha-granular proteins. Immunoelectron microscopy studies of the patients' platelets indicated that fibrinogen, von Willebrand factor, P-selectin, multimerin, and factor V were within alpha-granules, with normal to reduced labeling for these proteins. Pathologic proteolysis of alpha-granular contents, rather than a defect in targeting proteins to alpha-granules, may be the cause of the protein degradation in the Quebec platelet disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028947

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Diagnosis and Management of Inherited Platelet Disorders.

Authors:  Carl Maximilian Kirchmaier; Daniele Pillitteri
Journal:  Transfus Med Hemother       Date:  2010-09-15       Impact factor: 3.747

2.  Current Strategies in Diagnosis of Inherited Storage Pool Defects.

Authors:  Kirstin Sandrock; Barbara Zieger
Journal:  Transfus Med Hemother       Date:  2010-09-15       Impact factor: 3.747

Review 3.  Platelet alpha-granules: basic biology and clinical correlates.

Authors:  Price Blair; Robert Flaumenhaft
Journal:  Blood Rev       Date:  2009-05-17       Impact factor: 8.250

4.  Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation.

Authors:  D Kika Veljkovic; Georges E Rivard; Maria Diamandis; Jessica Blavignac; Elisabeth M Cramer-Bordé; Catherine P M Hayward
Journal:  Blood       Date:  2008-11-24       Impact factor: 22.113

5.  The duplication mutation of Quebec platelet disorder dysregulates PLAU, but not C10orf55, selectively increasing production of normal PLAU transcripts by megakaryocytes but not granulocytes.

Authors:  Catherine P M Hayward; Minggao Liang; Subia Tasneem; Asim Soomro; John S Waye; Andrew D Paterson; Georges E Rivard; Michael D Wilson
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

6.  Quantitative 3D microscopy highlights altered von Willebrand factor α-granule storage in patients with von Willebrand disease with distinct pathogenic mechanisms.

Authors:  Maurice Swinkels; Ferdows Atiq; Petra E Bürgisser; Johan A Slotman; Adriaan B Houtsmuller; Cilia de Heus; Judith Klumperman; Frank W G Leebeek; Jan Voorberg; Arend Jan Gerard Jansen; Ruben Bierings
Journal:  Res Pract Thromb Haemost       Date:  2021-09-14

7.  Thrombin generation abnormalities in Quebec platelet disorder.

Authors:  Justin G Brunet; Tanmya Sharma; Subia Tasneem; Minggao Liang; Michael D Wilson; Georges E Rivard; Catherine P M Hayward
Journal:  Int J Lab Hematol       Date:  2020-08-06       Impact factor: 2.877

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.